SPARC · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 96/100 — Quality 91 · Valuation 100 · Momentum 100
| Share price | ₹227.51 |
| Market cap | ₹8,587 Cr |
| P/E ratio | 5.5 |
| P/B ratio | 6.4 |
| ROCE | 112.0% |
| Book value | ₹41.25 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,879 Cr | ₹1,553 Cr | 85.0% |
| 2025 | ₹72 Cr | ₹-343 Cr | -450.0% |
| 2024 | ₹76 Cr | ₹-387 Cr | -532.0% |
| 2023 | ₹239 Cr | ₹-223 Cr | -90.0% |
| 2022 | — | — | — |
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clini